BD Biosciences, a segment of BD (Becton, Dickinson and Co.), announced plans to expand manufacturing in Puerto Rico and to begin production of selected reagent products there starting in 2007.
The $42 million capital investment project is expected to create more than 100 new jobs at the Cayey, Puerto Rico, facility, which currently supports 250 BD employees in the manufacture of products for the BD Diagnostics segment. This new capacity is intended to supplement current production at BD's existing facilities in San Diego and San Jose, Calif.
“Puerto Rico has assumed a vital role in an exciting growth area for BD,” said Edward J. Ludwig, chairman, president and CEO of BD. “Our long-term commitments here will help us meet the increasing demand worldwide for our BD Biosciences products. This development is the result of BD’s continuous focus on improving our operating effectiveness.”
Both new and expanded capacity will be contained in two new buildings across the street from the existing facility.
The initial facility is expected to bring more than 40,000 square feet of new manufacturing space in early 2007, and an additional 25,000 square feet is planned for mid-2009.
“This expansion will allow BD to meet growing demand for our monoclonal reagents for cell analysis, while enabling us to optimize our global production and supply chains for related products,” said Vince Forlenza, president of BD Biosciences.
Go to INTERNATIONAL SPOTLIGHTS to read more about other news and articles about international expansions.
Go to INDUSTRY SPOTLIGHTS to read more about other news and articles about this industry sector.
